Los Angeles Capital Management LLC Takes Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Los Angeles Capital Management LLC acquired a new stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 257,779 shares of the company’s stock, valued at approximately $469,000.

Other institutional investors have also recently added to or reduced their stakes in the company. EntryPoint Capital LLC acquired a new position in shares of ALX Oncology during the first quarter worth $32,000. Point72 Asset Management L.P. bought a new stake in shares of ALX Oncology in the 2nd quarter valued at about $1,834,000. California State Teachers Retirement System increased its stake in shares of ALX Oncology by 413.8% in the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock valued at $254,000 after buying an additional 18,360 shares during the period. Swiss National Bank bought a new position in shares of ALX Oncology during the first quarter worth about $493,000. Finally, Marshall Wace LLP lifted its stake in shares of ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares during the period. 97.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on ALXO shares. Stifel Nicolaus reissued a “hold” rating and set a $3.00 target price (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. UBS Group dropped their target price on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a report on Tuesday, August 13th. Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.50.

ALX Oncology Trading Down 3.0 %

NASDAQ:ALXO opened at $1.29 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology Holdings Inc. has a one year low of $1.25 and a one year high of $17.83. The company has a market cap of $68.04 million, a PE ratio of -0.43 and a beta of 1.03. The firm has a 50-day moving average of $1.69 and a 200-day moving average of $5.49.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.